Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 24, 2023, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France.
The prior notice of meeting comprising the agenda and draft resolutions was published in the BALO (Bulletin des Annonces Légales Obligatoires) on April 19, 2023, and the convening notice shall be published in a newspaper empowered to publish legal notices on May 3, 2023.
The documents provided for in articles R.22-10-23 of the French Commercial Code, are available for consultation on the company’s website mentioned below as of today, the twenty-first day prior to the General Meeting: www.sensorion.com.
In accordance with articles R.225-83 of the French Commercial Code, documents are available for the shareholders from the time the meeting is convened. In accordance with applicable regulations:
- any registered shareholders can, until the fifth day (inclusive) before the Meeting, request from the Company to receive these documents, including at their request, by way of an electronic mail. For holders of bearer shares, the exercise of this right is subject to the presentation of a certificate of attendance in the bearer share accounts kept by the empowered intermediary;
- any shareholder may consult these documents at the registered office of the Company.
For any questions relating to the Annual General Meeting of May 24, 2023, shareholders are invited to send an email to firstname.lastname@example.org.
The conditions for holding and taking part in this Combined Shareholders’ General Meeting may evolve depending on the health, regulatory and legal requirements in place. In general, shareholders are invited to regularly consult the section dedicated to the General Meeting on the Company's website www.sensorion.com.
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of gene therapies to restore hearing loss disorders, a significant global unmet medical need.
Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. OTOF-GT targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders.
Sensorion’s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2022 full year financial report published on March 30, 2023, and available on our website and to the development of economic conditions, financial markets, and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
David Lawrence, Chief Financial Officer (US/UK)
Noémie Djokovic, Investor Relations and Communications (Europe/France)
International Media Relations
Consilium Strategic Communications
Jessica Hodgson/Sue Stuart
+44 7593 572720
+44 7561 424788